This site is intended for Healthcare professionals only.

USFDA issues no observation on Zydus Ahmedabad facility


USFDA issues no observation on Zydus Ahmedabad facility

New Delhi: Zydus Cadila’s wholly-owned subsidiary Alidac Pharmaceuticals has not received any observation from the US health regulator after the closure of inspection of its manufacturing facility located at SEZ, Ahmedabad.

“The US Food and Drug Administration (USFDA) inspected the manufacturing facility of our wholly-owned subsidiary, Alidac Pharmaceuticals Ltd, located at SEZ, Ahmedabad from May 28 to June 5, 2018. At the end of the inspection, no observation (483) is issued,” the company said in a BSE filing.

The site manufactures oncology injectables for the regulated markets, it added.



Source: PTI
0 comment(s) on USFDA issues no observation on Zydus Ahmedabad facility

Share your Opinion Disclaimer

Sort by: Newest | Oldest | Most Voted